SAN

99.11

-3.51%↓

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

SAN

99.11

-3.51%↓

265.5

-0.82%↓

SHL.DE

49.33

-1.62%↓

ARGX

524.6

-3.81%↓

FRE

38.83

-1.89%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

3.038 -2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.018

Max

3.262

Põhinäitajad
By Trading Economics
Sissetulek	-22M
Müük	9.3M
Kasumimarginaal	-235.461
Töötajad	110
EBITDA	-23M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+301.23% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	2. apr 2025

Turustatistika
By TradingEconomics
Turukapital	156M
Eelmine avamishind	5.04
Eelmine sulgemishind	3.038

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

3.232 / 3.304 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1. apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1. apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1. apr 2025, 23:11 UTC

Peamised uudised

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1. apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:32 UTC

Peamised uudised

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1. apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1. apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2025, 20:47 UTC

Peamised uudised

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1. apr 2025, 20:47 UTC

Peamised uudised

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1. apr 2025, 20:20 UTC

Peamised uudised

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1. apr 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Fibrebond >ETN

1. apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1. apr 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. apr 2025, 20:00 UTC

Peamised uudised

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1. apr 2025, 19:46 UTC

Peamised uudised

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1. apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1. apr 2025, 19:17 UTC

Peamised uudised

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1. apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1. apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1. apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1. apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

301.23% tõus

12 kuu keskmine prognoos

Keskmine 13 EUR 301.23%

Kõrge 16 EUR

Madal 10 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.232 / 3.304Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.